Jann C, Giofre S, Bhattacharjee R, Lemke E
Chem Rev. 2024; 124(18):10281-10362.
PMID: 39120726
PMC: 11441406.
DOI: 10.1021/acs.chemrev.3c00878.
Kul E, Okoroafor U, Dougherty A, Palkovic L, Li H, Valino-Ramos P
Mol Ther Methods Clin Dev. 2024; 32(2):101243.
PMID: 38605812
PMC: 11007541.
DOI: 10.1016/j.omtm.2024.101243.
Selt F, El Damaty A, Schuhmann M, Sigaud R, Ecker J, Sievers P
J Neurooncol. 2023; 165(3):467-478.
PMID: 37999877
PMC: 10752915.
DOI: 10.1007/s11060-023-04500-6.
Page A, Delles M, Negre D, Costa C, Fusil F, Cosset F
Mol Ther Nucleic Acids. 2023; 33:1-14.
PMID: 37359346
PMC: 10285500.
DOI: 10.1016/j.omtn.2023.05.024.
Reichenbach P, Giordano Attianese G, Ouchen K, Cribioli E, Triboulet M, Ash S
Nat Biomed Eng. 2023; 7(9):1063-1080.
PMID: 37069267
PMC: 10504085.
DOI: 10.1038/s41551-023-01013-5.
Visualizing cell-cell communication using synthetic notch activated MRI.
Wang T, Chen Y, Nystrom N, Liu S, Fu Y, Martinez F
Proc Natl Acad Sci U S A. 2023; 120(11):e2216901120.
PMID: 36893267
PMC: 10089199.
DOI: 10.1073/pnas.2216901120.
T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts.
Nasiri F, Safarzadeh Kozani P, Rahbarizadeh F
Front Immunol. 2023; 14:1063838.
PMID: 36875091
PMC: 9978144.
DOI: 10.3389/fimmu.2023.1063838.
Modern Advances in CARs Therapy and Creating a New Approach to Future Treatment.
Sadowski K, Olejarz W, Basak G
Int J Mol Sci. 2022; 23(23).
PMID: 36499331
PMC: 9739283.
DOI: 10.3390/ijms232315006.
CRISPR/Cas9: a tool to eradicate HIV-1.
Bhowmik R, Chaubey B
AIDS Res Ther. 2022; 19(1):58.
PMID: 36457057
PMC: 9713993.
DOI: 10.1186/s12981-022-00483-y.
In vivo lentiviral vector gene therapy to cure hereditary tyrosinemia type 1 and prevent development of precancerous and cancerous lesions.
Nicolas C, VanLith C, Hickey R, Du Z, Hillin L, Guthman R
Nat Commun. 2022; 13(1):5012.
PMID: 36008405
PMC: 9411607.
DOI: 10.1038/s41467-022-32576-7.
Efficient derivation of chimeric-antigen receptor-modified T cells.
Kranz E, Kuhlmann C, Chan J, Kim P, Chen I, Kamata M
Front Immunol. 2022; 13:877682.
PMID: 35967430
PMC: 9366550.
DOI: 10.3389/fimmu.2022.877682.
Characterizing piggyBat-a transposase for genetic modification of T cells.
Sutrave G, Xu N, Tang T, Dolnikov A, Gloss B, Gottlieb D
Mol Ther Methods Clin Dev. 2022; 25:250-263.
PMID: 35474955
PMC: 9018555.
DOI: 10.1016/j.omtm.2022.03.012.
Nanobody-based CAR-T cells for cancer immunotherapy.
Safarzadeh Kozani P, Naseri A, Mirarefin S, Salem F, Nikbakht M, Evazi Bakhshi S
Biomark Res. 2022; 10(1):24.
PMID: 35468841
PMC: 9036779.
DOI: 10.1186/s40364-022-00371-7.
Hexon modification of human adenovirus type 5 vectors enables efficient transduction of human multipotent mesenchymal stromal cells.
Nilson R, Lubbers O, Schmidt C, Rojewski M, Zeplin P, Funk W
Mol Ther Methods Clin Dev. 2022; 25:96-110.
PMID: 35402633
PMC: 8956844.
DOI: 10.1016/j.omtm.2022.03.004.
Recent trends in miRNA therapeutics and the application of plant miRNA for prevention and treatment of human diseases.
Saiyed A, Vasavada A, Johar S
Futur J Pharm Sci. 2022; 8(1):24.
PMID: 35382490
PMC: 8972743.
DOI: 10.1186/s43094-022-00413-9.
Selective cleavage of ncRNA and antiviral activity by RNase2/EDN in THP1-induced macrophages.
Lu L, Li J, Wei R, Guidi I, Cozzuto L, Ponomarenko J
Cell Mol Life Sci. 2022; 79(4):209.
PMID: 35347428
PMC: 8960563.
DOI: 10.1007/s00018-022-04229-x.
Etched 3D-Printed Polycaprolactone Constructs Functionalized with Reduced Graphene Oxide for Enhanced Attachment of Dental Pulp-Derived Stem Cells.
Bow A, Masi T, Dhar M
Pharmaceutics. 2021; 13(12).
PMID: 34959426
PMC: 8704510.
DOI: 10.3390/pharmaceutics13122146.
Targeting Inflammasome Activation in COVID-19: Delivery of RNA Interference-Based Therapeutic Molecules.
Gedefaw L, Ullah S, Lee T, Yip S, Huang C
Biomedicines. 2021; 9(12).
PMID: 34944639
PMC: 8698532.
DOI: 10.3390/biomedicines9121823.
Neurobeachin, a promising target for use in the treatment of alcohol use disorder.
Cuzon Carlson V, Aylwin C, Carlson T, Ford M, Mesnaoui H, Lomniczi A
Addict Biol. 2021; 27(1):e13107.
PMID: 34699111
PMC: 8813173.
DOI: 10.1111/adb.13107.
Conditioned CAR-T cells by hypoxia-inducible transcription amplification (HiTA) system significantly enhances systemic safety and retains antitumor efficacy.
He H, Liao Q, Zhao C, Zhu C, Feng M, Liu Z
J Immunother Cancer. 2021; 9(10).
PMID: 34615704
PMC: 8496395.
DOI: 10.1136/jitc-2021-002755.